Similar articles

• Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents.

  Goodwin PJ, Stambolic V, Lemieux J, Chen BE, Parulekar WR, Gelmon KA, Hershman DL, Hobday TJ, Ligibel JA, Mayer IA, Pritchard KI, Whelan TJ, Rastogi P, Shepherd LE. Goodwin PJ, et al. Breast Cancer Res Treat. 2011 Feb;126(1):215-20. doi: 10.1007/s10549-010-1224-1. Epub 2010 Oct 26. Breast Cancer Res Treat. 2011. PMID: 20976543 Review.
• Clinical outcomes after radical prostatectomy in diabetic patients treated with metformin.

  Patel T, Hruby G, Badani K, Abate-Shen C, McKiernan JM. Patel T, et al. Urology. 2010 Nov;76(5):1240-4. doi: 10.1016/j.urology.2010.03.059. Urology. 2010. PMID: 20627287
• Metformin as an addition to conventional chemotherapy in breast cancer.

  Grenader T, Goldberg A, Shavit L. Grenader T, et al. J Clin Oncol. 2009 Dec 10;27(35):e259; author reply e260. doi: 10.1200/JCO.2009.25.4110. Epub 2009 Nov 2. J Clin Oncol. 2009. PMID: 19884518 No abstract available.
• Anticancer effects of metformin and its potential use as a therapeutic agent for breast cancer.

  Guppy A, Jamal-Hanjani M, Pickering L. Guppy A, et al. Future Oncol. 2011 Jun;7(6):727-36. doi: 10.2217/fon.11.49. Future Oncol. 2011. PMID: 21675836 Review.
• Long-term metformin use is associated with decreased risk of breast cancer.

  Bodmer M, Meier C, Krähenbühl S, Jick SS, Meier CR. Bodmer M, et al. Diabetes Care. 2010 Jun;33(6):1304-8. doi: 10.2337/dc09-1791. Epub 2010 Mar 18. Diabetes Care. 2010. PMID: 20299480 Free PMC article.